Stay updated with breaking news from Patricka Ott. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In a Phase 1 study among eight patients with advanced melanoma who received the NeoVax vaccine, after a median of four years, all of the patients remained alive and six patients had no signs of active disease.
Date Time Personalized vaccine produces long-lasting anti-tumor response in patients with melanoma, study shows Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard report in a new study. The findings, published online today by the journal Nature Medicine, demonstrate the staying power of the immune response generated by the vacci...
E-Mail BOSTON - Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and the Broad Institute of MIT and Harvard report in a new study. The findings, published online today by the journal Nature Medicine, demonstrate the staying power of the immune response generated by the vaccine, known as NeoVax, which works by targeting specific proteins on each patient's tumor cells. ...